MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- DR. REDDYS LAB - MYLAN (US)
DR. REDDYS LAB vs MYLAN (US) - Comparison Results
DR. REDDYS LAB Change
Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More
MYLAN (US)
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
Financials
 DR. REDDYS LAB  MYLAN |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| DR. REDDYS LAB Mar-20 |
MYLAN Dec-18 |
DR. REDDYS LAB/ MYLAN |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 3,363 | 3,487 | - | |
| Low | Rs | 2,352 | 1,919 | - | |
| Sales per share (Unadj.) | Rs | 1,054.2 | 1,604.6 | - | |
| Earnings per share (Unadj.) | Rs | 121.9 | 43.6 | - | |
| Cash flow per share (Unadj.) | Rs | 190.2 | 344.0 | - | |
| Dividends per share (Unadj.) | Rs | 25.00 | 0 | - | |
| Dividend yield (eoy) | % | 0.9 | 0 | - | |
| Book value per share (Unadj.) | Rs | 938.7 | 1,735.9 | - | |
| Shares outstanding (eoy) | m | 166.17 | 514.50 | - | |
| Bonus/Rights/Conversions | ESOP | - | - | ||
| Price / Sales ratio | x | 2.7 | 1.7 | 160.9% | |
| Avg P/E ratio | x | 23.4 | 62.0 | 37.8% | |
| P/CF ratio (eoy) | x | 15.0 | 7.9 | 191.2% | |
| Price / Book Value ratio | x | 3.0 | 1.6 | 195.5% | |
| Dividend payout | % | 20.5 | 0 | - | |
| Avg Mkt Cap | Rs m | 474,831 | 1,390,845 | 34.1% | |
| No. of employees | `000 | 21.7 | 35.0 | 61.9% | |
| Total wages/salary | Rs m | 33,802 | 0 | - | |
| Avg. sales/employee | Rs Th | 8,091.0 | 23,587.6 | 34.3% | |
| Avg. wages/employee | Rs Th | 1,561.3 | 0 | - | |
| Avg. net profit/employee | Rs Th | 935.8 | 640.5 | 146.1% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 175,170 | 825,567 | 21.2% | |
| Other income | Rs m | 6,206 | 0 | - | |
| Total revenues | Rs m | 181,376 | 825,567 | 22.0% | |
| Gross profit | Rs m | 24,421 | 213,626 | 11.4% | |
| Depreciation | Rs m | 11,348 | 154,579 | 7.3% | |
| Interest | Rs m | 983 | 39,707 | 2.5% | |
| Profit before tax | Rs m | 18,296 | 19,341 | 94.6% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 561 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | -1,403 | -3,077 | 45.6% | |
| Profit after tax | Rs m | 20,260 | 22,418 | 90.4% | |
| Gross profit margin | % | 13.9 | 25.9 | 53.9% | |
| Effective tax rate | % | -7.7 | -15.9 | 48.2% | |
| Net profit margin | % | 11.6 | 2.7 | 425.9% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 125,991 | 460,996 | 27.3% | |
| Current liabilities | Rs m | 72,141 | 336,117 | 21.5% | |
| Net working cap to sales | % | 30.7 | 15.1 | 203.2% | |
| Current ratio | x | 1.7 | 1.4 | 127.3% | |
| Inventory Days | Days | 73 | 84 | 87.4% | |
| Debtors Days | Days | 105 | 93 | 112.3% | |
| Net fixed assets | Rs m | 83,854 | 160,146 | 52.4% | |
| Share capital | Rs m | 831 | 440 | 189.1% | |
| Net worth | Rs m | 155,988 | 893,113 | 17.5% | |
| Long term debt | Rs m | 1,304 | 963,955 | 0.1% | |
| Total assets | Rs m | 232,253 | 2,395,675 | 9.7% | |
| Interest coverage | x | 19.6 | 1.5 | 1,318.8% | |
| Debt to equity ratio | x | 0 | 1.1 | 0.8% | |
| Sales to assets ratio | x | 0.8 | 0.3 | 218.9% | |
| Return on assets | % | 9.1 | 2.6 | 352.7% | |
| Return on equity | % | 13.0 | 2.5 | 517.4% | |
| Return on capital | % | 12.6 | 3.2 | 396.7% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 29,841 | 171,553 | 17.4% | |
| From Investments | Rs m | -4,923 | -88,674 | 5.6% | |
| From Financial Activity | Rs m | -25,159 | -79,919 | 31.5% | |
| Net Cashflow | Rs m | -266 | 1,421 | -18.7% | |
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 73.26 Rs / USD
Compare DR. REDDYS LAB With: ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
Compare DR. REDDYS LAB With: VENUS REMEDIES PFIZER ABBOTT INDIA SUN PHARMA DR. DATSONS LABS
Today's Market
Sensex Zooms 500 Points; Grasim Industries & HDFC Bank Top Gainers(09:30 am)
Asian share markets are trading on a mixed note tracking a mixed Wall Street session following a big downturn in tech shares.
Related Views On News
Most Popular
It's the Beginning of a New Bull Phase in Smallcaps (Profit Hunter)
Feb 24, 2021Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
Make Rs 5,000 Per Day Trading the Market (Fast Profits Daily)
Feb 25, 2021In this video, I'll show you how to get started on the path to daily trading profits.
Charge Your Portfolio with this Smallcap Proxy Play on India's EV Revolution (Profit Hunter)
Mar 5, 2021This could be the biggest wealth creator of the decade.
Gold 65,000 and Silver 84,000 in 2022
Feb 26, 2021In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.
More
